InspireMD, Inc., headquartered in Illinois, is a pioneering medical device company specialising in innovative solutions for the treatment of cardiovascular diseases. Founded in 2006, InspireMD has made significant strides in the industry, particularly with its proprietary MGuard™ technology, which combines a unique mesh design with a drug-eluting stent to enhance patient outcomes. With a focus on improving the safety and efficacy of vascular interventions, InspireMD operates primarily in North America and Europe, positioning itself as a leader in the interventional cardiology market. The company has achieved notable milestones, including successful clinical trials and regulatory approvals, solidifying its reputation for excellence in medical innovation. Through its commitment to advancing cardiovascular care, InspireMD continues to set itself apart with cutting-edge products that address critical patient needs.
How does InspireMD, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
InspireMD, Inc.'s score of 14 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
InspireMD, Inc., headquartered in Illinois, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that InspireMD may not yet have established a comprehensive climate strategy or may be in the early stages of developing one. As the company operates within the medical device industry, it is essential for InspireMD to consider the growing emphasis on sustainability and carbon reduction within the sector. Many organisations are increasingly adopting Science-Based Targets Initiative (SBTi) guidelines and committing to net-zero emissions, which could serve as a benchmark for InspireMD in future climate initiatives. Overall, while InspireMD has not yet disclosed specific emissions data or reduction commitments, the industry context highlights the importance of establishing a robust climate strategy to align with global sustainability goals.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
InspireMD, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
